In line Q2; correction of late is an entry point
27/07/26 -"The Q2 26 results were largely in line with the street’s expectations. Strong growth in oncology, respiratory, immunology and rare disease treatments more than compensated for the expected ..."
Pages
70
Language
English
Published on
27/07/26
You may also be interested by these reports :
27/07/26
The Q2 26 results were largely in line with the street’s expectations. Strong growth in oncology, respiratory, immunology and rare disease treatments ...
23/07/26
Despite FX headwinds, the Q2 results were ahead of the street’s expectations. The performance was driven by drugs across therapeutic areas, and the ...
22/07/26
Lonza published its 1H results, with a strong operating performance but a mixed revenue outcome. The group grew by +16% (CER) YoY, with strong FX ...
21/07/26
The Q2 sales growth was supported by a healthy showing across both segments. The management now expects full-year growth to be at the upper end of ...